The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis

References

• Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4–27.
   PubMed Web of Science ®Google Scholar
• Neve A, Cantatore FP, Maruotti N, Corrado A, Ribatti D. Extracellular matrix modulates angiogenesis in physiological and pathological conditions. Biomed Res Int. 2014;2014:756078.
   PubMed Web of Science ®Google Scholar
• Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360:1989–2003.
   PubMed Web of Science ®Google Scholar
• Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev. 2011;10:590–4.
   PubMed Web of Science ®Google Scholar
• Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 2002;4:R11.
   PubMedGoogle Scholar
• Ebmeier S, Horsley V. Origin of fibrosing cells in systemic sclerosis. Curr Opin Rheumatol. 2015;27(6):555.
   PubMed Web of Science ®Google Scholar
• Cipriani P, Di Benedetto P, Ruscitti P, Liakouli V, Berardicuti O, Carubbi F, et al. Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis. J Rheumatol. 2016;43:1340–9.
   PubMed Web of Science ®Google Scholar
• Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int. 2011;31:1409–17.
   PubMed Web of Science ®Google Scholar
• Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaissè J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000;486:247–51.
   PubMed Web of Science ®Google Scholar
• Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 2000;60:5410–3.
   PubMed Web of Science ®Google Scholar
• Bellon G, Martiny L, Robinet A. Matrix metalloproteinases and matrikines in angiogenesis. Crit Rev Oncol Hematol. 2004;49:203–20.
   PubMed Web of Science ®Google Scholar
• Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 2007;361:79–84.
   PubMed Web of Science ®Google Scholar
• Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engström A, et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood. 2000;95:3403–11.
   PubMed Web of Science ®Google Scholar
• Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum. 2000;43:889–93.
   PubMed Web of Science ®Google Scholar
• Reiseter S, Molberg Ø, Gunnarsson R, Lund MB, Aalokken TM, Aukrust P, et al. Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study. Arthritis Res Ther. 2015;17:231.
   PubMed Web of Science ®Google Scholar
• Hummers LK, Hall A, Wigley FM, Simons M. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol. 2009;36:576–82.
   PubMed Web of Science ®Google Scholar
• Dziankowska-Bartkowiak B, Waszczykowska E, Zalewska A, Sysa-Jedrzejowska AA. Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediators Inflamm. 2005;2005:144–9.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Feghali-Bostwick CA. Role of endostatin in fibroproliferative disorders as a candidate for anti-fibrosis therapy. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36:452–8.
   PubMedGoogle Scholar
• Jimenez SA, Feldman G, Bashey RI, Bienkowski R, Rosenbloom J. Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis fibroblasts. Biochem J. 1986;237:837–43.
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 2006;54:2271–9.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang J. Detection of V, III and I type collagens of dermal tissues in skin lesions of patients with systemic sclerosis and its implication. J Huazhong Univ Sci Technol Med Sci. 2008;28:599–603.
   PubMed Web of Science ®Google Scholar
• Verrecchia F, Mauviel A. Transforming growth factor-beta and fibrosis. World J Gastroenterol. 2007;13:3056–62.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Borderie D, Lemaréchal H, Cherruau B, Ekindjian OG, Kahan A. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol. 2003;30:68–73.
   PubMed Web of Science ®Google Scholar
• Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol. 2004;36:961–8.
   PubMed Web of Science ®Google Scholar
• Wang S, Wu Z, Sorenson CM, Lawler J, Sheibani N. Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn. 2003;228:630–42.
   PubMed Web of Science ®Google Scholar
• Kyriakides TR, Zhu YH, Smith LT, Bain SD, Yang Z, Lin MT, et al. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol. 1998;140:419–30.
   PubMed Web of Science ®Google Scholar
• Streit M, Velasco P, Riccardi L, Spencer L, Brown LF, Janes L, et al. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J. 2000;19:3272–82.
   PubMed Web of Science ®Google Scholar
• Morgan-Rowe L, Nikitorowicz J, Shiwen X, Leask A, Tsui J, Abraham D, et al. Thrombospondin 1 in hypoxia-conditioned media blocks the growth of human microvascular endothelial cells and is increased in systemic sclerosis tissues. Fibrogenesis Tissue Repair. 2001;4:13.
   Google Scholar
• Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, Dvorak HF, et al. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J. 2009;23:3368–76.
   PubMed Web of Science ®Google Scholar
• Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000;6:41–8.
   PubMed Web of Science ®Google Scholar
• Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000;11:59–69.
   PubMed Web of Science ®Google Scholar
• Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts. Am J Pathol. 2005;166:1451–63.
   PubMed Web of Science ®Google Scholar
• Farina G, Lafyatis D, Lemaire R, Lafyatis R. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2010;62:580–8.
   PubMed Web of Science ®Google Scholar
• Krady MM, Zeng J, Yu J, MacLauchlan S, Skokos EA, Tian W, et al. Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. Am J Pathol. 2008;173:879–91.
   PubMed Web of Science ®Google Scholar
• Bornstein P, Kyriakides TR, Yang Z, Armstrong LC, Birk DE. Thrombospondin 2 modulates collagen fibrillogenesis and angiogenesis. J Investig Dermatol Symp Proc. 2000;5:61–6.
   PubMed Web of Science ®Google Scholar
• Armstrong LC, Björkblom B, Hankenson KD, Siadak AW, Stiles CE, Bornstein P. Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell. 2002;13:1893–905.
   PubMed Web of Science ®Google Scholar
• Kajihara I, Jinnin M, Yamane K, Makino T, Honda N, Igata T, et al. Increased accumulation of extracellular thrombospondin-2 due to low degradation activity stimulates type I collagen expression in scleroderma fibroblasts. Am J Pathol. 2012;180:703–14.
   PubMed Web of Science ®Google Scholar
• Reinecke H, Robey TE, Mignone JL, Muskheli V, Bornstein P, Murry CE. Lack of thrombospondin-2 reduces fibrosis and increases vascularity around cardiac cell grafts. Cardiovasc Pathol. 2013;22(1):91–5.
   PubMed Web of Science ®Google Scholar
• Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med. 2011;15:1013–31.
   PubMed Web of Science ®Google Scholar
• Teng YH, Aquino RS, Park PW. Molecular functions of syndecan-1 in disease. Matrix Biol. 2012;31:3–16.
   PubMed Web of Science ®Google Scholar
• De Rossi G, Whiteford JR. Syndecans in angiogenesis and endothelial cell biology. Biochem Soc Trans. 2014;42(6):1643–6.
   PubMed Web of Science ®Google Scholar
• Jing Z, Wei-Jie Y, Yi-Feng ZG, Jing H. Downregulation of Syndecan-1 induce glomerular endothelial cell dysfunction through modulating internalization of VEGFR-2. Cell Signal. 2016;28:826–37.
   PubMed Web of Science ®Google Scholar
• Rapraeger AC, Ell BJ, Roy M, Li X, Morrison OR, Thomas GM, et al. Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between αVβ3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis. FEBS J. 2013;280:2194–206.
   PubMed Web of Science ®Google Scholar
• Wu CY, Asano Y, Taniguchi T, Sato S, Yu HS. Serum level of circulating syndecan-1: a possible association with proliferative vasculopathy in systemic sclerosis. J Dermatol. 2016;43:63–6.
   PubMed Web of Science ®Google Scholar
• Chen E, Hermanson S, Ekker SC. Syndecan-2 is essential for angiogenic sprouting during zebrafish development. Blood. 2004;103:1710–9.
   PubMed Web of Science ®Google Scholar
• Fears CY, Gladson CL, Woods A. Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells. J Biol Chem. 2006;281:14533–6.
   PubMed Web of Science ®Google Scholar
• Noguer O, Villena J, Lorita J, Vilaró S, Reina M. Syndecan-2 downregulation impairs angiogenesis in human microvascular endothelial cells. Exp Cell Res. 2009;315:795–808.
   PubMed Web of Science ®Google Scholar
• De Rossi G, Evans AR, Kay E, Woodfin A, McKay TR, Nourshargh S, et al. Shed syndecan-2 inhibits angiogenesis. J Cell Sci. 2014;127:4788–99.
   PubMed Web of Science ®Google Scholar
• Ruiz XD, Mlakar LR, Yamaguchi Y, Su Y, Larregina AT, Pilewski JM, et al. Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis. PLoS One. 2012;7:e43049.
   PubMed Web of Science ®Google Scholar
• Shi Y, Gochuico BR, Yu G, Tang X, Osorio JC, Fernandez IE, et al. Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-β receptor I internalization and inhibiting transforming growth factor-β1 signaling. Am J Respir Crit Care Med. 2013;188:831–41.
   PubMed Web of Science ®Google Scholar
• Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, et al. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res. 2013;73:1097–106.
   PubMed Web of Science ®Google Scholar
• Bălănescu P, Lădaru A, Bălănescu E, Voiosu T, Băicuş C, Dan GA. Endocan, novel potential biomarker for systemic sclerosis: results of a pilot study. J Clin Lab Anal. 2016;30:368–73.
   PubMed Web of Science ®Google Scholar
• Chen Y, Leask A, Abraham DJ, Pala D, Shiwen X, Khan K, et al. Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts. Arthritis Rheum. 2008;58:577–85.
   PubMed Web of Science ®Google Scholar
• Chang YT, Chan CK, Eriksson I, Johnson PY, Cao X, Westöö C, et al. Versican accumulates in vascular lesions in pulmonary arterial hypertension. Pulm Circ. 2016;6:347–59.
   PubMed Web of Science ®Google Scholar
• Bensadoun ES, Burke AK, Hogg JC, Roberts CR. Proteoglycan deposition in pulmonary fibrosis. Am J Respir Crit Care Med. 1996;154:1819–28.
   PubMed Web of Science ®Google Scholar
• Gabrielsen A, Lawler PR, Yongzhong W, Steinbrüchel D, Blagoja D, Paulsson-Berne G, et al. Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium. J Mol Cell Cardiol. 2007;42:870–83.
   PubMed Web of Science ®Google Scholar
• Hesselstrand R, Westergren-Thorsson G, Scheja A, Wildt M, Åkesson A. The association between changes in skin echogenicity and the fibroblast production of biglycan and versican in systemic sclerosis. Clin Exp Rheumatol. 2002;20:301–8.
   PubMed Web of Science ®Google Scholar
• Masuda A, Yasuoka H, Satoh T, Okazaki Y, Yamaguchi Y, Kuwana M. Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop. Arthritis Res Ther. 2013;15:R74.
   PubMed Web of Science ®Google Scholar
• Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal. 2009;3:287–310.
   PubMed Web of Science ®Google Scholar
• Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006;244:143–63.
   PubMed Web of Science ®Google Scholar
• Lacour JP, Vitetta A, Chiquet-Ehrismann R, Pisani A, Ortonne JP. Increased expression of tenascin in the dermis in scleroderma. Br J Dermatol. 1992;127:328–34.
   PubMed Web of Science ®Google Scholar
• Jinnin M, Ihn H, Asano Y, Yamane K, Trojanowska M, Tamaki K. Upregulation of tenascin-C expression by IL-13 in human dermal fibroblasts via the phosphoinositide 3-kinase/Akt and the protein kinase C signaling pathways. J Invest Dermatol. 2006;126:551–60.
   PubMed Web of Science ®Google Scholar
• Brissett M, Veraldi KL, Pilewski JM, Medsger TA Jr., Feghali-Bostwick CA. Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3. Arthritis Rheum. 2012;64:272–80.
   PubMed Web of Science ®Google Scholar
• Tourkina E, Hoffman S, Fenton JW, Lipsitz S, Silver RM, Ludwicka-Bradley A. Depletion of protein kinase C epsilon in normal and scleroderma lung fibroblasts has opposite effects on tenascin expression. Arthritis Rheum. 2001;44:1370–81.
   PubMed Web of Science ®Google Scholar
• Inoue K, Jinnin M, Hara Y, Makino K, Kajihara I, Makino T, et al. Serum levels of tenascin-C in collagen diseases. J Dermatol. 2013;40:715–9.
   PubMed Web of Science ®Google Scholar
• Makhluf HA, Stepniakowska J, Hoffman S, Smith E, LeRoy EC, Trojanowska M. IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J Invest Dermatol. 1996;107:856–9.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Wang W, Morales-Nebreda L, Feng G, Wu M, Zhou X, et al. Tenascin-C drives persistence of organ fibrosis. Nat Commun. 2016;7:11703.
   PubMed Web of Science ®Google Scholar
• Rundhaug JE. Matrix metalloproteinases and angiogenesis. Structure and function of matrix metalloproteinases and TIMPs. J Cell Mol Med. 2005;9:267–85.
   PubMed Web of Science ®Google Scholar
• Peng WJ, Yan JW, Wan YN, Wang BX, Tao JH, Yang GJ, et al. Matrix metalloproteinases: a review of their structure and role in systemic sclerosis. J Clin Immunol. 2012;32:1409–14.
   PubMed Web of Science ®Google Scholar
• Manetti M, Guiducci S, Romano E, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, et al. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis. 2012;71(6):1064–72.
   PubMed Web of Science ®Google Scholar
• D’Alessio S, Fibbi G, Cinelli M, Guiducci S, Del Rosso A, Margheri F, et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum. 2004;50:3275–85.
   PubMed Web of Science ®Google Scholar
• Fibbi G, Caldini R, Chevanne M, Pucci M, Schiavone N, Morbidelli L, et al. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. Lab Invest. 1998;78:1109–19.
   PubMed Web of Science ®Google Scholar
• Serratì S, Cinelli M, Margheri F, Guiducci S, Del Rosso A, Pucci M, et al. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. J Pathol. 2006;210:240–8.
   PubMed Web of Science ®Google Scholar
• Manetti M, Ibba-Manneschi L, Fatini C, Guiducci S, Cuomo G, Bonino C, et al. Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population. J Rheumatol. 2010;37:1852–7.
   PubMed Web of Science ®Google Scholar
• Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood). 2006;231:20–7.
   PubMed Web of Science ®Google Scholar
• Fujishima S, Shiomi T, Yamashita S, Yogo Y, Nakano Y, Inoue T, et al. Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis. Arch Pathol Lab Med. 2010;134:1136–42.
   PubMed Web of Science ®Google Scholar
• Ito TK, Ishii G, Saito S, Yano K, Hoshino A, Suzuki T, et al. Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood. 2009;113:2363–9.
   PubMed Web of Science ®Google Scholar
• Huo N, Ichikawa Y, Kamiyama M, Ishikawa T, Hamaguchi Y, Hasegawa S, et al. MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells. Cancer Lett. 2002;177:95–100.
   PubMed Web of Science ®Google Scholar
• Moinzadeh P, Krieg T, MJürgen H, Brinckmann J, Neumann E, Müller-Ladner U, et al. Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement. Exp Dermatol. 2011;20:770–3.
   PubMed Web of Science ®Google Scholar
• Hawinkels LJ, Zuidwijk K, Verspaget HW, de Jonge-Muller ESM, van Duijn W, Ferreira V, et al. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer. 2008;44:1904–13.
   PubMed Web of Science ®Google Scholar
• Heljasvaara R, Nyberg P, Luostarinen J, Parikka M, Heikkilä P, Rehn M, et al. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp Cell Res. 2005;307:292–304.
   PubMed Web of Science ®Google Scholar
• Giannelli G, Iannone F, Marinosci F, Lapadula G, Antonaci S. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin. 2005;21:327–32.
   PubMed Web of Science ®Google Scholar
• Skarmoutsou E, D’Amico F, Marchini M, Stivala F, Malaponte G, Scorza R, et al. Analysis of matrix metalloproteinase-9 gene polymorphism -1562 C/T in patients suffering from systemic sclerosis with and without ulcers. Int J Mol Med. 2011;27:873–7.
   PubMed Web of Science ®Google Scholar
• Andersen GN, Nilsson K, Pourazar J, Hackett TL, Kazzam E, Blomberg A, et al. Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis. Respir Med. 2007;101:2199–206.
   PubMed Web of Science ®Google Scholar
• Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol. 2003;120:542–7.
   PubMed Web of Science ®Google Scholar
• Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K, et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol. 2004;138:357–63.
   PubMed Web of Science ®Google Scholar
• Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, Okada Y. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem. 2002;277:36288–95.
   PubMed Web of Science ®Google Scholar
• Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 2006;38:2018–39.
   PubMed Web of Science ®Google Scholar
• Wu CY, Asano Y, Taniguchi T, Sato S, Yu HS. Serum heparanase levels: a protective marker against digital ulcers in patients with systemic sclerosis. J Dermatol. 2015;42:625–8.
   PubMed Web of Science ®Google Scholar
• Bignon M, Pichol-Thievend C, Hardouin J, Malbouyres M, Bréchot N, Nasciutti L, et al. Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane. Blood. 2011;118:3979–89.
   PubMed Web of Science ®Google Scholar
• Osawa T, Ohga N, Akiyama K, Hida Y, Kitayama K, Kawamoto T, et al. Lysyl oxidase secreted by tumour endothelial cells promotes angiogenesis and metastasis. Br J Cancer. 2013;109:2237–47.
   PubMed Web of Science ®Google Scholar
• Rimar D, Rosner I, Nov Y, Slobodin G, Rozenbaum M, Halasz K, et al. Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis. Arthritis Rheumatol. 2014;66:726–30.
   PubMed Web of Science ®Google Scholar
• Frohlich C, Klitgaard M, Noer JB, Kotzsch A, Nehammer C, Kronqvist P, et al. ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins. Biochem J. 2013;452:97–109.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Asano Y, Akamata K, Aozasa N, Noda S, Takahashi T, et al. Serum levels of ADAM12-S: possible association with the initiation and progression of dermal fibrosis and interstitial lung disease in patients with systemic sclerosis. J Eur Acad Dermatol Venereol. 2013;27:747–53.
   PubMed Web of Science ®Google Scholar
• Raghu G, Scholand MB, de Andrade J, Lancaster L, Mageto Y, Goldin J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: Results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Respir J. 2016;47:1481–91.
   PubMed Web of Science ®Google Scholar
• Leask A. CCN2: a mechanosignaling sensor modulating integrin-dependent connective tissue remodeling in fibroblasts? J Cell Commun Signal. 2013;7:203–5.
   PubMed Web of Science ®Google Scholar
• Wang Q, Usinger W, Nichols B, Gray J, Xu L, Seeley TW, et al. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis Tissue Repair. 2011;4:4.
   PubMedGoogle Scholar
• Liu S, Leask A. CCN2 is not required for skin development. J Cell Commun Signal. 2011;5:179–82.
   PubMed Web of Science ®Google Scholar
• Makino K, Makino T, Stawski L, Lipson KE, Leask A, Trojanowska M. Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis. Arthritis Res Ther. 2017;19:134.
   PubMed Web of Science ®Google Scholar
• Huang J, Beyer C, Palumbo-Zerr K, Zhang Y, Ramming A, Distler A, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis. 2016;75:883–90.
   PubMed Web of Science ®Google Scholar